ELI LILLY & (LLY) Company Report

China’s NMPA cleared the IND for ST-01156, enabling inclusion of Chinese clinical sites in SEED’s planned global expansion study
ST-01156 is SEED’s first clinical candidate, with FDA Orphan Drug and Rare Pediatric Disease designations for Ewing sarcoma
Preclinical data showed complete tumor regression in xenograft models and strong RBM39 target engagement, supporting expansion into RBM39-dependent cancers

Nov 12, 2025, 12:00 PM

Press Release

Eli Lilly shares surge on analyst upgrade and Medicare obesity deal

LLY

Revenue Acceleration/Inflection

Debt Issuance

Product Launch

Leerink Partners upgraded Eli Lilly to Outperform, raising its price target to $1,104, driven by obesity treatment adoption and expanded Medicare/Medicaid access starting 2027.
New pricing agreement expands the pool of eligible Medicare obesity treatment patients from 8.5 million to 40 million, significantly boosting market potential.
Q3 revenue reached $17.60 billion (53.9% y/y) with EPS of $7.02, and the balance sheet shows a current ratio of 1.55 and debt-to-equity of 1.79, following $25.4 billion of new debt over three years.
Upcoming obesity drugs include orforglipron in 2027 and eloralintide in 2028, the latter delivering 16.4% weight loss at 48 weeks in Phase 2 trials and projected for $10.7 billion in risk-adjusted sales.
Analysts project a 15% revenue CAGR and 20% EPS CAGR through 2030 for Eli Lilly.

Nov 10, 2025, 1:46 PM

Morningstar

Eli Lilly enters $75M ophthalmology collaboration with MeiraGTx

LLY

New Projects/Investments

$75 million upfront, plus potential milestone payments exceeding $400 million and tiered royalties, for exclusive global rights to MeiraGTx’s AAV-AIPL1 gene therapy targeting Leber congenital amaurosis 4.
MeiraGTx shares rose 15–18% in premarket trading on the news.
MeiraGTx’s financials highlight a –416.49% operating margin, –415.39% net margin, current and quick ratios of 0.88, and an Altman Z-Score of –5.66.
The deal reinforces MeiraGTx’s leadership in genetic medicine and advances Eli Lilly’s ophthalmology portfolio.

Nov 10, 2025, 12:36 PM

Morningstar

Eli Lilly's Eloralintide Delivers Up to 20% Weight Loss in Phase 2 Trial

LLY

New Projects/Investments

Eloralintide induced up to 20.1% body weight reduction over 48 weeks, with the highest 9 mg dose yielding an average weight loss of ~21.3 kg.
Trial involved adults with obesity/overweight and weight-related comorbidities (no type 2 diabetes); side effects were mostly mild/moderate gastrointestinal symptoms and fatigue, with improved tolerability via dose escalation.
Eli Lilly plans to initiate pivotal phase 3 trials and is exploring combining eloralintide with its GLP-1 therapy tirzepatide to enhance treatment options.
Amylin receptor agonist profile may offer lower lean muscle loss relative to fat mass compared to GLP-1 drugs, potentially improving body composition outcomes.

Nov 7, 2025, 12:06 AM

Bloomberg

BioAge Labs reports third quarter 2025 results and clinical updates

LLY

Earnings

New Projects/Investments

Third quarter 2025 collaboration revenue was $2.1 M, research and development expenses $18.5 M, general and administrative expenses $6.7 M, and net loss $20.2 M ( $0.56 per share ).
Cash, cash equivalents, and marketable securities totaled $295.9 M as of September 30, 2025, providing runway through 2029 under current plans.
First participant dosed in the Phase 1 trial of BGE-102, an oral CNS-penetrant NLRP3 inhibitor, with initial single ascending dose data expected by year-end 2025.
Oral and parenteral APJ agonist programs advanced toward IND submissions in 2026.
Ongoing research collaborations with Novartis and Lilly ExploR&D to identify and develop novel metabolic aging targets.

Nov 6, 2025, 9:45 PM

Press Release

Lilly announces executive committee expansions and leadership role enhancements

LLY

Management Change

Hiring

Carole Ho, M.D. joins as executive vice president and president, Lilly Neuroscience, and becomes an Executive Committee member, bringing over 20 years in neurology and rare disease development.
Adrienne Brown is promoted to executive vice president and president, Lilly Immunology, joining the Executive Committee after 20+ years with Lilly, including leading the U.S. launch of Mounjaro.
Daniel Skovronsky, M.D., Ph.D., expands his role as chief scientific and product officer and president of Lilly Research Laboratories, overseeing R&D and global product strategy.
Jacob Van Naarden assumes additional oversight of corporate business development while continuing as executive vice president and president, Lilly Oncology.
These changes are designed to accelerate Lilly's pipeline, generate new portfolio opportunities, and strengthen patient access to medicines, according to CEO David A. Ricks.

Nov 6, 2025, 9:05 PM

Press Release

Lilly expands government-backed access to obesity treatments

LLY

New Projects/Investments

Product Launch

Agreement to cap Medicare out-of-pocket cost at $50/month for Zepbound and orforglipron starting April 1, 2026, with optional Medicaid expansion by states.
Self-pay access via LillyDirect: Zepbound pen priced $299–$449 per dose (refills capped at $449) and orforglipron priced $149–$399.
Emgality, Trulicity and Mounjaro added to LillyDirect with 50–60% discounts; insulin remains capped at $35/month for all patients.
Commitment of >$50 billion to U.S. manufacturing investments and securing three years of tariff relief.

Nov 6, 2025, 6:54 PM

Press Release

Eli Lilly reports positive Phase 2 results for eloralintide in obesity treatment

LLY

Eli Lilly’s selective amylin agonist eloralintide achieved mean weight reductions of 9.5%–20.1% across dose arms versus 0.4% with placebo at 48 weeks in 263 adults with obesity or overweight and ≥1 comorbidity.
The 48-week, randomized, double-blind, placebo-controlled Phase 2 trial evaluated once-weekly eloralintide monotherapy in adults without type 2 diabetes.
Safety was favorable, with mostly mild-to-moderate gastrointestinal symptoms and fatigue; slower dose escalation reduced adverse event incidence, and the 1 mg and 3 mg arms had similar tolerability to placebo.
Based on these data, Lilly plans to begin Phase 3 clinical studies by year-end.

Nov 6, 2025, 11:45 AM

Press Release

Lilly plans new $3B oral medicines facility in Netherlands

LLY

New Projects/Investments

Hiring

$3 billion facility in Katwijk, Netherlands, to expand oral solid medicines manufacturing, including orforglipron, Lilly’s first oral GLP-1 agonist (regulatory submission expected by year-end)
Incorporates advanced technologies like dock-to-dock automation and paperless manufacturing to strengthen Lilly’s global supply chain
Expected to create 500 permanent high-wage jobs and 1,500 construction jobs, with construction slated to start next year pending government permits
Part of Lilly’s broader manufacturing expansion in Europe—augmenting sites in France, Ireland, Italy and Spain—and aligned with its goal of carbon neutrality and zero waste operations

Nov 3, 2025, 1:30 PM

Press Release

Eli Lilly raises guidance as obesity drug sales surge

LLY

Guidance Update

Revenue Acceleration/Inflection

M&A

Eli Lilly’s obesity drugs Zepbound and Mounjaro generated $10.1 billion in combined Q3 sales, surpassing Merck’s Keytruda at $8.1 billion
The company raised its full-year revenue and earnings forecasts following the strong performance
Strong financial investment and innovation are fueling a pipeline of new high-impact drugs through the early 2030s
A bidding war for Metsera, involving Novo Nordisk and Pfizer, sees Novo planning to pay up to $9 billion for the drugmaker

Oct 30, 2025, 10:39 PM

Morningstar

Filings & Transcripts

View All Documents

Recent SEC filings and earnings call transcripts for LLY.

No recent filings or transcripts found for LLY.